The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ACRIN 6688 phase II study of fluorine-18 3′-deoxy-3′ fluorothymidine (FLT) in invasive breast cancer.
P. R. Jolles
No relevant relationships to disclose
L. Kostakoglu
No relevant relationships to disclose
H. D. Bear
No relevant relationships to disclose
M. O. Idowu
No relevant relationships to disclose
K. A. Kurdziel
No relevant relationships to disclose
L. Shankar
No relevant relationships to disclose
D. A. Mankoff
Stock Ownership - Bristol-Myers Squibb; Pfizer
Research Funding - Merck; Pfizer
F. Duan
No relevant relationships to disclose
D. L'Heureux
No relevant relationships to disclose